Synchron Raises US$200 Million in Series D Funding to Advance BCI Technology
Synchron has secured US$200 million in a Series D financing round. The funding will be used to accelerate the commercialisation of its first-generation Stentrode brain-computer interface (BCI) and to further develop a next-generation, transcatheter, high-channel whole-brain interface.
Funding Goals and Development Plans
According to a company statement, this capital injection will speed up pivotal trials, prepare for the market launch of the Stentrode system, and support hiring additional engineers, neuroscientists, and operational staff to advance upcoming BCI technologies.
“Bolstered by this Series D funding, Synchron will continue to expand its team and capabilities to bring the next generation of brain-computer interfaces closer to reality.”
Investors and Strategic Backing
- Lead investor: Double Point Ventures
- Participating existing investors: ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, METIS
- New investors: Australian National Reconstruction Fund (NRF), T Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, IQT
With this latest round, Synchron’s total funding now stands at US$345 million, according to its latest release.
Author’s Summary
Synchron’s new US$200 million investment strengthens its position in brain-computer interface innovation, supporting commercial rollout and next-generation research.